SCHEMBL4399387

SCHEMBL4399387

COC(=S)Nc1ccncc1.NC(O)=S

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
LMNA P02545 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
EPHX1 P07099 2/20 0.46
MDM2 Q00987 1/20 0.44
ALDH1A1 P00352 5/20 0.43
TAAR1 Q96RJ0 1/20 0.43
MEN1 O00255 1/20 0.43
PKM P14618 1/20 0.43
KMT2A Q03164 1/20 0.43
JAK2 O60674 1/20 0.41
TYK2 P29597 1/20 0.41
KDM4E B2RXH2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
BCHE P06276 1/20 0.40
TP53 P04637 1/20 0.39
TYR P14679 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6963209 0.82 ALDH1A1 (0.59) SMN1; SMN2LMNAALDH1A1MEN1KMT2A
SCHEMBL8977667 0.80 ALDH1A1 (0.55) SMN1; SMN2LMNAALDH1A1PKMKMT2A
Methane SCHEMBL18335057 0.79 MDM2 (0.48) LMNAEPHX1MDM2ALDH1A1TAAR1
SCHEMBL8977679 0.78 MAPT (0.52) SMN1; SMN2LMNAEPHX1ALDH1A1MEN1
SCHEMBL8977748 0.78 CYP1A2 (0.61) SMN1; SMN2LMNATDP1ALDH1A1MEN1
SCHEMBL1615892 0.76 TAS2R38 (0.60) SMN1; SMN2LMNAEPHX1ALDH1A1MEN1
SCHEMBL526209 0.76 ALDH1A1 (0.60) SMN1; SMN2EPHX1MDM2ALDH1A1TAAR1
SCHEMBL8103756 0.75 SMN1; SMN2 (0.52) SMN1; SMN2LMNAALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL31091389 0.74 ALDH1A1 (0.58) SMN1; SMN2EPHX1MDM2ALDH1A1TAAR1
SCHEMBL9297614 0.73 MDM2 (0.56) LMNAEPHX1MDM2ALDH1A1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1300401-B1 THIAZOLE DERIVATIVES FOR USE AS ANTIINFLAMMATORIES DAINIPPON SUMITOMO PHARMA CO (JP) 2009-12-09 EP disclosed
US-7396842-B2 Five-membered cyclic compounds DIANIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-07-08 US disclosed
EP-1669070-A2 2-imino-thiazolidine and -oxazolidine derivatives for use as antiinflammatory agents Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-06-14 EP disclosed
US-20050222226-A1 Five-membered cyclic compounds SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2005-10-06 US disclosed
US-6919361-B2 Five-membered-ring compound SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-07-19 US disclosed
US-20040072827-A1 Five-membered-ring compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2004-04-15 US disclosed
EP-1300401-A1 FIVE-MEMBERED-RING COMPOUND SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072827-A1 Five-membered-ring compound EPX, IL5, CCR9 SMN1; SMN2 3887/4885LMNA 4315/4885TDP1 4800/4885
US-20050222226-A1 Five-membered cyclic compounds EPX, CCL11, CCR9 SMN1; SMN2 3889/4885LMNA 3956/4885TDP1 4784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.